Abstract:Phase I clinical trials represent the first step in bringing promising new treatments from the laboratory to the clinic. Although the importance of phase I clinical trials is widely recognized, there is currently no consensus among the scientific, medical, and statistical communities on how best to do these studies in humans. With the advent of targeted therapies, it has become evident that we need to tailor the design of phase I studies for the particular drug class under investigation and any endpoints that are being defined. The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) provides broad external scientific and clinical input on the design and prioritization of early-phase clinical trials with agents for which the NCI Cancer Therapy Evaluation Program (CTEP) holds an Investigational New Drug (IND) application through the U.S. Food and Drug Administration (FDA). The IDSC has formed a number of task forces and working groups, including the Clinical Trial Design Task Force and the Biomarker Working Group, many with membership from within the IDSC as well as external experts, including participants from academia, the pharmaceutical industry, and regulatory authorities. The Clinical Trials Design Taskforce sponsored a Phase I Workshop with the primary goal being to develop consensus recommendations for the optimal design of phase I studies. The primary focus included (1) efficient trial designs, (2) phase I drug combinations, and (3) appropriate statistical and correlative endpoints. In this CCR Focus series, articles summarize key aspects and recommendations on phase I studies (including combination trials), such as design, use of biomarkers, the European Union and Japanese perspectives on design, requirements for first-in-human and other phase I studies, and ensuring regulatory and International Conference on Harmonization (ICH) compliance. A final article summarizes recommendations for the design and conduct of phase II studies.

Inclusion of Histopathology in Dose Range-Finding Nonclinical Studies for Inhaled Drug Products

Phase 0 trials/ Intra-Target-Microdosing (ITM) and the lung: a review

Toxicologic Pathology Forum: Opinion on Not Euthanizing Control Animals in the Recovery Phase of Non-Rodent Toxicology Studies

Reevaluating safety pharmacology respiratory studies within the ICH S7A core battery: A multi-company evaluation of preclinical utility and clinical translation

Review of the Technical, Toxicological, and PKPD Considerations for Conducting Inhalation Toxicity Studies on Biologic Pharmaceuticals—The Outcome of a Cross-Industry Working Group Survey

Clinically Relevant In Vitro Testing of Orally Inhaled Products—Bridging the Gap Between the Lab and the Patient

Do longer duration nonclinical toxicology studies provide predictive clinical safety value? The IQ consortium longer duration nonclinical to clinical translational database

History of Chronic Toxicity and Animal Carcinogenicity Studies for Pharmaceuticals

Adaptive Dose Modification for Phase I Clinical Trials

Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

New Approach Methodology for Assessing Inhalation Risks of a Contact Respiratory Cytotoxicant: Computational Fluid Dynamics-Based Aerosol Dosimetry Modeling for Cross-Species and In Vitro Comparisons

The importance of variations in in vitro dosimetry to support risk assessment of inhaled toxicants

Lung function measurements in rodents in safety pharmacology studies

On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

Improved laboratory test methods for orally inhaled products

Practical Considerations in Dose Extrapolation from Animals to Humans

The Role of Animal Pathology in the Risk Control of New Drug

Comparison of Oral, Intranasal and Aerosol Administration of Amiodarone in Rats as a Model of Pulmonary Phospholipidosis

Innovative preclinical models for pulmonary drug delivery research

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics

Exploring rabbit as a nonrodent species for general toxicology studies